SREBF1 and prostate cancer: Evidence suggests that the MAPK signaling pathway is also involved in control of lipid metabolism following the observation that p38α inhibition impairs cholesterol homeostasis via inactivation of SREBP1, leading to restricted cancer cell proliferation in liver and prostate cancer.131